EP1737969A4 - PRODUCTION OF GALACTOSYLATE GLYCOPROTEINS IN LOWER EUKARYOTES - Google Patents

PRODUCTION OF GALACTOSYLATE GLYCOPROTEINS IN LOWER EUKARYOTES

Info

Publication number
EP1737969A4
EP1737969A4 EP05732293A EP05732293A EP1737969A4 EP 1737969 A4 EP1737969 A4 EP 1737969A4 EP 05732293 A EP05732293 A EP 05732293A EP 05732293 A EP05732293 A EP 05732293A EP 1737969 A4 EP1737969 A4 EP 1737969A4
Authority
EP
European Patent Office
Prior art keywords
galactosylate
glycoproteins
production
lower eukaryotes
eukaryotes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP05732293A
Other languages
German (de)
French (fr)
Other versions
EP1737969A2 (en
EP1737969B1 (en
EP1737969B2 (en
Inventor
Robert Davidson
Tillman Gerngross
Stefan Wildt
Byung-Kwon Choi
Juergen Nett
Piotr Bobrowicz
Stephen Hamilton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlycoFi Inc
Original Assignee
GlycoFi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35150558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1737969(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlycoFi Inc filed Critical GlycoFi Inc
Publication of EP1737969A2 publication Critical patent/EP1737969A2/en
Publication of EP1737969A4 publication Critical patent/EP1737969A4/en
Publication of EP1737969B1 publication Critical patent/EP1737969B1/en
Application granted granted Critical
Publication of EP1737969B2 publication Critical patent/EP1737969B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP05732293.5A 2004-04-15 2005-04-15 Production of galactosylated glycoproteins in lower eukaryotes Expired - Lifetime EP1737969B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56242404P 2004-04-15 2004-04-15
PCT/IB2005/051249 WO2005100584A2 (en) 2004-04-15 2005-04-15 Production of galactosylated glycoproteins in lower eukaryotes

Publications (4)

Publication Number Publication Date
EP1737969A2 EP1737969A2 (en) 2007-01-03
EP1737969A4 true EP1737969A4 (en) 2011-09-28
EP1737969B1 EP1737969B1 (en) 2015-06-17
EP1737969B2 EP1737969B2 (en) 2018-09-12

Family

ID=35150558

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05732293.5A Expired - Lifetime EP1737969B2 (en) 2004-04-15 2005-04-15 Production of galactosylated glycoproteins in lower eukaryotes

Country Status (6)

Country Link
EP (1) EP1737969B2 (en)
JP (2) JP2007535317A (en)
CN (2) CN104611245A (en)
AU (1) AU2005233387B2 (en)
CA (1) CA2562772A1 (en)
WO (1) WO2005100584A2 (en)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
US7507573B2 (en) * 2003-11-14 2009-03-24 Vib, Vzw Modification of protein glycosylation in methylotrophic yeast
CN103145837A (en) 2005-06-30 2013-06-12 Abbvie公司 IL-12/P40 binding proteins
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500353A3 (en) 2005-08-19 2012-10-10 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20140053410A (en) 2005-08-19 2014-05-07 아보트 러보러터리즈 Dual variable domain immunoglobulin and uses thereof
CN101277974A (en) 2005-09-30 2008-10-01 阿伯特有限及两合公司 Binding domains of proteins of the Repulsive Guide Molecule (RGM) protein family, functional fragments thereof and their uses
RU2442793C2 (en) 2005-11-30 2012-02-20 Эбботт Лэборетриз ANTISUBSTANCES AGAINST GLOBULOMER Aβ, THEIR ANTIGEN-BINDING PARTS, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, WAYS OF PRODUCTION OF MENTIONED ANTISUBSTANCES, COMPOSITIONS CONTAINING MENTIONED ANTISUBSTANCES, APPLICATION OF MENTIONED ANTISUBSTANCES AND WAYS OF APPLICATION OF MENTIONED ANTISUBSTANCES
PL1976877T5 (en) 2005-11-30 2017-09-29 Abbvie Inc Monoclonal antibodies against amyloid beta protein and uses thereof
JP5110563B2 (en) * 2006-03-03 2012-12-26 独立行政法人産業技術総合研究所 Method for producing mucin-type sugar chain binding protein
HUE052220T2 (en) 2006-09-08 2021-04-28 Abbvie Bahamas Ltd Interleukin-13 binding proteins
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
JP5967861B2 (en) 2007-04-03 2016-08-10 オキシレイン ユーケー リミテッド Glycosylation of molecules
IL182956A0 (en) 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN102089430B (en) 2008-05-09 2015-02-04 Abbvie公司 Antibodies against receptor for progressive glycation end products (RAGE) and uses thereof
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab Dual variable domain immunoglobulins and uses thereof
KR20110016959A (en) 2008-06-03 2011-02-18 아보트 러보러터리즈 Dual Variable Domain Immunoglobulins and Uses thereof
KR20110040886A (en) 2008-07-08 2011-04-20 아보트 러보러터리즈 Prostaglandin E2 binding protein and uses thereof
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
EP2401378B1 (en) * 2009-02-25 2013-08-14 Merck Sharp & Dohme Corp. Metabolic engineering of a galactose assimilation pathway in the glycoengineered yeast pichia pastoris
US8283162B2 (en) 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof
CA2763105A1 (en) * 2009-05-28 2010-12-02 Eth Zurich N-glycan core beta-galactosyltransferase and uses thereof
MX2012002651A (en) 2009-09-01 2012-05-22 Abbott Lab Dual variable domain immunoglobulins and uses thereof.
KR102000383B1 (en) 2009-09-29 2019-07-15 유니버시테이트 젠트 Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
AR078651A1 (en) 2009-10-15 2011-11-23 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
US8420083B2 (en) 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
US20130053550A1 (en) 2009-11-19 2013-02-28 Oxyrane Uk Limited Yeast strains producing mammalian-like complex n-glycans
PH12012501070A1 (en) 2009-12-08 2017-08-23 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
TWI500427B (en) 2010-05-14 2015-09-21 Abbvie Inc Il-1 binding proteins
CN102030823A (en) * 2010-06-21 2011-04-27 中国人民解放军军事医学科学院放射与辐射医学研究所 Liver-targeted genetically engineered interferon and preparation method thereof
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (en) 2010-07-09 2012-01-31 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
US9120862B2 (en) 2010-07-26 2015-09-01 Abbott Laboratories Antibodies relating to PIVKA-II and uses thereof
KR20130100118A (en) 2010-08-03 2013-09-09 아비에 인코포레이티드 Dual variable domain immunoglobulins and uses therof
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
JP6131190B2 (en) 2010-09-29 2017-05-17 オキシレイン ユーケー リミテッド Demannosylation of phosphorylated N-glycans
BR112013007616B1 (en) 2010-09-29 2023-01-24 Oxyrane Uk Limited METHODS FOR DECAPPING ("UNCAPPING") PORTIONS OF MANNOSE-1-PHOSPHO-6-MANNOSE AND DEMANNOSYLING PHOSPHORYLATED N-GLYCANS TO A GLYCOPROTEIN, FOR DIRECTING A GLYCOPROTEIN INTO A MAMMALIAN CELL, AND FOR CONVERTING A GLYCOPROTEIN IN A FIRST WAY THAT DOES NOT SUBSTANTIALLY BINDING TO A MANNOSE-6-PHOSPHATE RECEPTOR IN A SECOND WAY THAT SUBSTANTIALLY BINDS TO A MANNOSE-6-PHOSPHATE RECEPTOR ON A MAMMALIAN CELL
MX2013007332A (en) 2010-12-21 2014-01-23 Abbvie Inc Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use.
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2719761B1 (en) * 2011-06-07 2018-01-24 Kikkoman Corporation Flavin-binding glucose dehydrogenase, method for manufacturing flavin-binding glucose dehydrogenase, and glucose measurement method using same
SG10201505454SA (en) 2011-07-13 2015-09-29 Abbvie Inc Methods and compositions for treating asthma using anti-il-13 antibodies
CN103827134A (en) 2011-07-20 2014-05-28 泽普泰恩股份有限公司 Polypeptide separation methods
AR089529A1 (en) 2011-12-30 2014-08-27 Abbvie Inc UNION PROTEINS SPECIFIC DUALS DIRECTED AGAINST IL-13 AND / OR IL-17
AU2013211939C1 (en) 2012-01-27 2018-06-07 AbbVie Deutschland GmbH & Co. KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
CA2867237C (en) 2012-03-15 2024-01-02 Wouter Vervecken Methods and materials for treatment of pompe's disease
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
TWI595885B (en) 2012-05-02 2017-08-21 喜納製藥公司 Novel tetragalnac containing conjugates and methods for delivery of oligonucleotides
AR090905A1 (en) * 2012-05-02 2014-12-17 Merck Sharp & Dohme CONJUGATES CONTAINING TETRAGALNAC AND PEPTIDES AND PROCEDURES FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES, PHARMACEUTICAL COMPOSITION
AR091755A1 (en) 2012-07-12 2015-02-25 Abbvie Inc PROTEINS OF UNION TO IL-1
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
PE20151179A1 (en) 2012-11-01 2015-09-12 Abbvie Inc DUAL ANTI-VEGF / DLL4 VARIABLE DOMAIN IMMUNOGLOBULINS AND USES OF THEM
US9550986B2 (en) 2012-12-21 2017-01-24 Abbvie Inc. High-throughput antibody humanization
US9458244B2 (en) 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods
EP2938637A2 (en) 2012-12-28 2015-11-04 AbbVie Inc. Multivalent binding protein compositions
EP2948177A1 (en) 2013-01-22 2015-12-02 AbbVie Inc. Methods for optimizing domain stability of binding proteins
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014143342A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
MX362075B (en) 2013-03-14 2019-01-07 Abbott Lab Hcv antigen-antibody combination assay and methods and compositions for use therein.
CN105378099B (en) 2013-03-14 2021-05-11 雅培制药有限公司 HCV core lipid binding domain monoclonal antibodies
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
TWI731535B (en) 2014-03-21 2021-06-21 美商艾伯維有限公司 Anti-egfr antibodies and antibody drug conjugates
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
JP6518917B2 (en) 2015-05-29 2019-05-29 アッヴィ・インコーポレイテッド Anti-CD40 antibody and use thereof
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
CN109562190A (en) 2016-06-08 2019-04-02 艾伯维公司 Anti-EGFR Antibody Drug Conjugates
MX2018015284A (en) 2016-06-08 2019-09-18 Abbvie Inc Anti-egfr antibody drug conjugates.
CN109641962A (en) 2016-06-08 2019-04-16 艾伯维公司 Anti-B7-H3 Antibodies and Antibody Drug Conjugates
CN116059201A (en) 2016-06-08 2023-05-05 艾伯维公司 Anti-EGFR Antibody Drug Conjugate
JP2019526529A (en) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド Anti-B7-H3 antibody and antibody drug conjugate
RS61828B1 (en) 2016-06-08 2021-06-30 Abbvie Inc Anti-b7-h3 antibodies and antibody drug conjugates
WO2017214456A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
MX2018015268A (en) 2016-06-08 2019-08-12 Abbvie Inc Anti-cd98 antibodies and antibody drug conjugates.
MX2018015272A (en) 2016-06-08 2019-08-12 Abbvie Inc Anti-cd98 antibodies and antibody drug conjugates.
WO2018098370A1 (en) 2016-11-23 2018-05-31 Immunoah Therapeutics, Inc. 4-1bb binding proteins and uses thereof
EP3554544A4 (en) 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. ANTI-CUB-CONTAINING PROTEIN 1 (CDCP1) ANTIBODIES, ANTIBODY-ACTIVE SUBSTANCE CONJUGATES AND METHOD FOR USE THEREOF
WO2018195302A1 (en) 2017-04-19 2018-10-25 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
WO2018231827A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
CA3107038A1 (en) * 2018-08-10 2020-02-13 Genentech, Inc. Cell culture strategies for modulating protein glycosylation
BR112021010116A2 (en) * 2018-12-04 2021-08-31 Glycom A/S SYNTHESIS OF FUCOSYLATED OLIGOSACCHARIDE LNFP-V
KR20220137698A (en) 2020-02-05 2022-10-12 라리마 테라퓨틱스, 인코포레이티드 TAT peptide binding protein and uses thereof
AR124681A1 (en) 2021-01-20 2023-04-26 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES
US20240336946A1 (en) * 2021-04-16 2024-10-10 Merck Sharp & Dohme Llc Solid-phase glycan remodeling of glycoproteins
CN113265434B (en) * 2021-05-19 2023-05-02 吉林大学 Method for synthesizing UDP-galactose and method for synthesizing galactosyl compound
DK4186529T3 (en) 2021-11-25 2025-08-25 Veraxa Biotech Gmbh IMPROVED ANTIBODY-PAYLOAD CONJUGATES (APC) MANUFACTURED BY SITE-SPECIFIC CONJUGATION USING GENETIC CODE EXPANSION
JP2024543916A (en) 2021-11-25 2024-11-26 ヴェラクサ バイオテック ゲーエムベーハー Improved antibody-payload complexes (APCs) prepared by site-specific conjugation using genetic code expansion
CN114507658B (en) * 2022-04-02 2022-07-05 深圳瑞德林生物技术有限公司 Enzyme coexpression system and application thereof in synthesizing sialic acid
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
TW202530255A (en) 2023-12-15 2025-08-01 法商亞維西亞有限公司 Anti il-1rap binding domains and antibody-drug conjugates thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064618A1 (en) * 1998-06-08 1999-12-16 Dcv, Inc., Doing Business As Bio-Technical Resources Vitamin c production in microorganisms and plants
WO2001031045A1 (en) * 1999-10-26 2001-05-03 Plant Research International B.V. Mammalian-type glycosylation in plants
WO2002000879A2 (en) * 2000-06-28 2002-01-03 Glycofi, Inc. Methods for producing modified glycoproteins
WO2003056914A1 (en) * 2001-12-27 2003-07-17 Glycofi, Inc. Methods to engineer mammalian-type carbohydrate structures

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834251A (en) * 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
US6528286B1 (en) * 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
PT1137789E (en) † 1998-12-09 2010-10-21 Phyton Holdings Llc A method for manufacturing glycoproteins having human-type glycosylation
KR100637410B1 (en) * 1999-08-19 2006-10-23 기린 비루 가부시키가이샤 Method for preparing glycoproteins containing novel yeast mutant strains and mammalian sugar chains
CN1331290A (en) * 2000-06-26 2002-01-16 上海博德基因开发有限公司 Polypeptide-human beta-1,4 galactosyltransferase 18.59 and polynucleotide for coding it
US7449308B2 (en) † 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
CN100385006C (en) * 2001-01-19 2008-04-30 陶氏化学公司 Method for secretory production of glycoproteins with human sugar chains using plant cells
US6800739B2 (en) * 2001-04-05 2004-10-05 Davisco Foods International, Inc. Isolation of glycoproteins from bovine milk
PL213948B1 (en) * 2001-10-25 2013-05-31 Genentech Inc Glycoprotein compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064618A1 (en) * 1998-06-08 1999-12-16 Dcv, Inc., Doing Business As Bio-Technical Resources Vitamin c production in microorganisms and plants
WO2001031045A1 (en) * 1999-10-26 2001-05-03 Plant Research International B.V. Mammalian-type glycosylation in plants
WO2002000879A2 (en) * 2000-06-28 2002-01-03 Glycofi, Inc. Methods for producing modified glycoproteins
WO2003056914A1 (en) * 2001-12-27 2003-07-17 Glycofi, Inc. Methods to engineer mammalian-type carbohydrate structures

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOBROWICZ P ET AL: "Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose", GLYCOBIOLOGY, OXFORD UNIVERSITY PRESS, US, vol. 14, no. 9, 9 June 2004 (2004-06-09), pages 757 - 766, XP002354412, ISSN: 0959-6658, DOI: 10.1093/GLYCOB/CWH104 *
DATABASE Geneseq [online] 27 March 2000 (2000-03-27), "Amino acid sequence of a UDP-galactose 4-epimerase protein.", XP002648816, retrieved from EBI accession no. GSP:AAY54118 Database accession no. AAY54118 *
DATABASE UniProt [online] 1 November 1999 (1999-11-01), "RecName: Full=Uncharacterized protein C365.14c;", XP002648815, retrieved from EBI accession no. UNIPROT:Q9Y7X5 Database accession no. Q9Y7X5 *
LOPEZ-AVALOS MARIA DOLORES ET AL: "The UDPase activity of the Kluyveromyces lactis Golgi GDPase has a role in uridine nucleotide sugar transport into Golgi vesicles", GLYCOBIOLOGY, vol. 11, no. 5, May 2001 (2001-05-01), pages 413 - 422, XP002648814, ISSN: 0959-6658 *
See also references of WO2005100584A2 *
VERVECKEN W ET AL: "IN VIVO SYNTHESIS OF MAMMALIAN-LIKE, HYBRID-TYPE N-GLYCANS IN PICHIA PASTORIS", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 70, no. 5, 1 May 2004 (2004-05-01), pages 2639 - 2646, XP008032109, ISSN: 0099-2240, DOI: 10.1128/AEM.70.5.2639-2646.2004 *

Also Published As

Publication number Publication date
AU2005233387B2 (en) 2011-05-26
JP2007535317A (en) 2007-12-06
EP1737969A2 (en) 2007-01-03
JP5584660B2 (en) 2014-09-03
WO2005100584A3 (en) 2006-12-21
CA2562772A1 (en) 2005-10-27
AU2005233387A1 (en) 2005-10-27
CN1950496A (en) 2007-04-18
EP1737969B1 (en) 2015-06-17
WO2005100584A2 (en) 2005-10-27
JP2011254822A (en) 2011-12-22
CN104611245A (en) 2015-05-13
CN1950496B (en) 2015-02-04
EP1737969B2 (en) 2018-09-12

Similar Documents

Publication Publication Date Title
EP2027281A4 (en) PRODUCTION OF SIALYLATED N-GLYCANES IN LOWER EUCARYOTES
EP1876996A4 (en) Aesthetic thermal sculpting of skin
EP1845849A4 (en) EXOSQUELET OF LOWER MEMBERS
BRPI0919301A2 (en) appearance and management of window-specific controls
GB0600310D0 (en) Improvements relating to construction
GB0505064D0 (en) Production of bio-diesel
EP2155914A4 (en) IMPROVEMENTS IN THE PRODUCTION OF FERROALLIAGES
GB0623790D0 (en) Improvements in or relating to curtain walling
PL1800589T3 (en) Dishwasher and method of supplying water to the dishwasher
ES1060816Y (en) IMPROVED TACO
PT1781145T (en) Tool to facilitate the consumption of ingestible substances
GB2425547B (en) Improvements in or relating to building constructions
GB0508094D0 (en) Improvements to showers and baths
GB2426239B (en) Improvements in or relating to stairlifts
EP1885868A4 (en) Production of enzymes
EP2271780A4 (en) LIXIVIATION IN CASE OF LATERITY WITH FERROUS LIXIVIANTS
EP1946101A4 (en) In vivo detection of apoptosis
GB0508439D0 (en) Design of structural elements
GB2428664B (en) Improvements in or relating to stairlifts
DK1937808T3 (en) Enhancement of enzyme production
ES1067186Y (en) MULTIFUNCTIONAL PERSONAL ORNAMENT
FI7431U1 (en) Column corrosion and appearance cover
FIU20060441U0 (en) Column corrosion and appearance cover
GB2429448B (en) Improvements in or relating to stairlifts
TH0701003593A (en) Derivatives and analogues of N-ethylquinolone and N-ethyl saquinolone

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 1/19 20060101AFI20070119BHEP

Ipc: C07K 16/00 20060101ALI20070119BHEP

Ipc: C12P 21/00 20060101ALI20070119BHEP

DAX Request for extension of the european patent (deleted)
17P Request for examination filed

Effective date: 20070621

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: 8566

A4 Supplementary search report drawn up and despatched

Effective date: 20110829

RIC1 Information provided on ipc code assigned before grant

Ipc: C12P 21/00 20060101ALI20110823BHEP

Ipc: C12N 1/19 20060101AFI20110823BHEP

Ipc: C07K 16/00 20060101ALI20110823BHEP

17Q First examination report despatched

Effective date: 20120405

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602005046779

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C12P0021060000

Ipc: C12N0009100000

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 9/90 20060101ALI20141121BHEP

Ipc: C12N 9/10 20060101AFI20141121BHEP

Ipc: C12P 21/00 20060101ALI20141121BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150109

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 731962

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602005046779

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150617

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150617

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 731962

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150617

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

Ref country code: NL

Ref legal event code: MP

Effective date: 20150617

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150918

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150917

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150617

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151017

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150617

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150617

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150617

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150617

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150617

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150617

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151019

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602005046779

Country of ref document: DE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

26 Opposition filed

Opponent name: GLYKOS FINLAND OY

Effective date: 20160316

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150617

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150617

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160430

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150617

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160415

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150617

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160430

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160430

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160415

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150617

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150617

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150617

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20050415

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150617

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150617

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

27A Patent maintained in amended form

Effective date: 20180912

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R102

Ref document number: 602005046779

Country of ref document: DE

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230524

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240314

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240315

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240315

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 602005046779

Country of ref document: DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20250414

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20250414